ジヒドロピリミジン脱水素酵素、ジヒドロピリミジンデヒドロゲナーゼ
- 関
- dihydrouracil dehydrogenase NADP、DPD
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/10/06 04:59:47」(JST)
[Wiki en表示]
| dihydropyrimidine dehydrogenase |
| Identifiers |
| Symbol |
DPYD |
| Entrez |
1806 |
| HUGO |
3012 |
| OMIM |
274270 |
| RefSeq |
NM_000110 |
| Other data |
| EC number |
1.3.1.2 |
| Locus |
Chr. 1 p22 |
| Dihydropyrimidine dehydrogenase (NADP(+)) |
| Identifiers |
| EC number |
1.3.1.2 |
| CAS number |
9029-01-0 |
| Alt. names |
Dihydrothymine dehydrogenase |
| Databases |
| IntEnz |
IntEnz view |
| BRENDA |
BRENDA entry |
| ExPASy |
NiceZyme view |
| KEGG |
KEGG entry |
| MetaCyc |
metabolic pathway |
| PRIAM |
profile |
| PDB structures |
RCSB PDB PDBe PDBsum |
| Gene Ontology |
AmiGO / QuickGO |
| Search |
| PMC |
articles |
| PubMed |
articles |
| NCBI |
proteins |
|
Dihydropyrimidine dehydrogenase (DPD) is an enzyme that is involved in pyrimidine degradation. It is the initial and rate-limiting step in pyrimidine catabolism.[citation needed] It catalyzes the reduction of uracil and thymine.[1] It is also involved in the degradation of the chemotherapeutic drugs 5-fluorouracil and tegafur.[2]
See also
- Dihydropyrimidine dehydrogenase deficiency, a genetic disorder
References
- ^ Chung T, Na J, Kim YI, Chang DY, Kim YI, Kim H, Moon HE, Kang KW, Lee DS, Chung JK, Kim SS, Suh-Kim H, Paek SH, Youn H (2016). "Dihydropyrimidine Dehydrogenase Is a Prognostic Marker for Mesenchymal Stem Cell-Mediated Cytosine Deaminase Gene and 5-Fluorocytosine Prodrug Therapy for the Treatment of Recurrent Gliomas". Theranostics. 6 (10): 1477–90. PMC 4955049 . PMID 27446484. doi:10.7150/thno.14158.
- ^ Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, Schwab M (December 2013). "Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing". Clinical Pharmacology and Therapeutics. 94 (6): 640–5. PMC 3831181 . PMID 23988873. doi:10.1038/clpt.2013.172.
|
|
| Purine metabolism |
| Anabolism |
| R5P→IMP: |
- Ribose-phosphate diphosphokinase
- Amidophosphoribosyltransferase
- Phosphoribosylglycinamide formyltransferase
- AIR synthetase (FGAM cyclase)
- Phosphoribosylaminoimidazole carboxylase
- Phosphoribosylaminoimidazolesuccinocarboxamide synthase
- IMP synthase
|
| IMP→AMP: |
- Adenylosuccinate synthase
- Adenylosuccinate lyase
- reverse
|
| IMP→GMP: |
- IMP dehydrogenase
- GMP synthase
- reverse
|
|
| Nucleotide salvage |
- Hypoxanthine-guanine phosphoribosyltransferase
- Adenine phosphoribosyltransferase
|
| Catabolism |
- Adenosine deaminase
- Purine nucleoside phosphorylase
- Guanine deaminase
- Xanthine oxidase
- Urate oxidase
|
|
| Pyrimidine metabolism |
| Anabolism |
- CAD
- Carbamoyl phosphate synthase II
- Aspartate carbamoyltransferase
- Dihydroorotase
|
- Dihydroorotate dehydrogenase
- Orotidine 5'-phosphate decarboxylase/Uridine monophosphate synthetase
|
|
|
|
| Catabolism |
- Dihydropyrimidine dehydrogenase
- Dihydropyrimidinase/DPYS
- Beta-ureidopropionase/UPB1
|
|
| Deoxyribonucleotides |
- Ribonucleotide reductase
- Nucleoside-diphosphate kinase
- DCMP deaminase
- Thymidylate synthase
- Dihydrofolate reductase
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Pharmacokinetic and Pharmacodynamic Analyses of 5-Fluorouracil in East-Asian Patients with Nasopharyngeal Carcinoma.
- Ma Y1, Lin Y2, Zou B3, Liu W2, Zhang Y1, Zhao L4, Huang Y3, Yang Y3, Fang W3, Zhao Y3, Sheng J3, Qin T3, Hu Z3, Zhang L5, Zhao H6.
- Clinical pharmacokinetics.Clin Pharmacokinet.2016 Oct;55(10):1205-16. doi: 10.1007/s40262-016-0395-2.
- BACKGROUND AND OBJECTIVE: 5-Fluorouracil plus cisplatin is the most commonly used chemotherapy regimen for nasopharyngeal carcinoma (NPC). The objective of this study was to establish an individualized 5-fluorouracil treatment model based on pharmacokinetic and pharmacodynamic analyses of 5-fluorour
- PMID 27138786
- Advances and challenges in hereditary cancer pharmacogenetics.
- Cascorbi I1, Werk AN1.
- Expert opinion on drug metabolism & toxicology.Expert Opin Drug Metab Toxicol.2016 Sep 16:1-10. [Epub ahead of print]
- INTRODUCTION: Cancer pharmacogenetics usually considers tumor-specific targets. However, hereditary genetic variants may interfere with the pharmacokinetics of antimetabolites and other anti-cancer drugs, which may lead to severe adverse events.AREAS COVERED: Here, the impact of hereditary genes con
- PMID 27603572
- Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.
- Ma WW1, Saif MW2, El-Rayes BF3, Fakih MG4, Cartwright TH5, Posey JA6, King TR7, von Borstel RW8, Bamat MK8.
- Cancer.Cancer.2016 Sep 13. doi: 10.1002/cncr.30321. [Epub ahead of print]
- BACKGROUND: Increased susceptibility to 5-fluorouracil (5-FU)/capecitabine can lead to rapidly occurring toxicity caused by impaired clearance, dihydropyrimidine dehydrogenase deficiency, and other genetic variations in the enzymes that metabolize 5-FU. Life-threatening 5-FU overdoses occur because
- PMID 27622829
Japanese Journal
- Analysis of the mRNA Expression Levels of Thymidylate Synthase (TS), Dihydropyrimidine Dehydrogenase (DPD) and Orotate Phosphoribosyl Transferase (OPRT) in Liver Metastases from Colorectal Cancer.
- Colorectal cancer with high-frequency microsatellite instability expresses high-level thymidine phosphorylase but not dihydropyrimidine dehydrogenase
- Tsuji Takashi,Nakagoe Tohru,Jibiki Masaaki,Hisano Hiroshi,Nogawa Tatsuhiko,Sawai Terumitsu,Nagayasu Takeshi
- Acta medica Nagasakiensia 58(1), 1-7, 2013-04-00
- … The expressions of dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP) in tumor specimens were measured by enzymelinked immunosorbent assays. …
- NAID 110009576994
- Study protocol of the B-CAST study: a multicenter, prospective cohort study investigating the tumor biomarkers in adjuvant chemotherapy for stage III colon cancer
- Ishiguro Megumi,Kotake Kenjiro,Nishimura Genichi,Tomita Naohiro,Ichikawa Wataru,Takahashi Keiichi,Watanabe Toshiaki,Furuhata Tomohisa,Kondo Ken,Mori Masaki,Kakeji Yoshihiro,Kanazawa Akiyoshi,Kobayashi Michiya,Okajima Masazumi,Hyodo Ichinosuke,Miyakoda Keiko,Sugihara Kenichi,兵頭 一之介
- BMC cancer 13, 149, 2013-03-00
- … Protein expression of thymidine phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD), epidermal growth factor receptor (EGFR), and vascular endothelial growth factor (VEGF) are evaluated using enzyme-linked immunosorbent assay (ELISA). …
- NAID 120005246958
Related Links
- Dihydropyrimidine dehydrogenase deficiency is caused by mutations in the DPYD gene. This gene provides instructions for making an enzyme called dihydropyrimidine dehydrogenase, which is involved in the breakdown of molecules ...
- Dihydropyrimidine dehydrogenase (DPD) deficiency is inherited in an autosomal recessive manner. This means that in affected individuals, both copies of the DPYD gene in each cell (one inherited from each parent) have mutations
★リンクテーブル★
[★]
ジヒドロウラシル脱水素酵素(NADP依存性5-FU代謝酵素)
- 関
- dihydrouracil dehydrogenase(NAD)、dihydrouracil dehydrogenase(NADP)
- dihydropyrimidine dehydrogenase
[★]
- 英
- dihydropyrimidine dehydrogenase、DPD
- 関
- ジヒドロピリミジンデヒドロゲナーゼ、ジヒドロウラシル脱水素酵素
[★]
[★]
- 英
- dihydropyrimidine dehydrogenase、DPD
- 関
- ジヒドロピリミジン脱水素酵素
[★]
- 同
- dihydropyrimidine dehydrogenase
[★]
ジヒドロピリミジンデヒドロゲナーゼ欠損症候群
[★]
脱水素酵素 デヒドロゲナーゼ
[★]
脱水素酵素 デヒドロゲナーゼ
[★]
ジヒドロピリミジン